巨星醫療控股(02393.HK)2021年扭虧為盈至330萬元
格隆匯3月30日丨巨星醫療控股(02393.HK)公吿,截至2021年12月31日止年度的全年業績,收益同比增加約20.1%至約人民幣49.3億元。2021年歸屬於母公司擁有人的溢利約為人民幣330萬元,而2020年則錄得虧損約人民幣5.9億元。2021年的每股盈利為人民幣0.1分,而2020年則錄得每股虧損人民幣25.0分。董事會不建議就2021年度派發末期股息(2020年:無)。
政府堅定不移地抗擊COVID-19,令中國醫院及診所能夠於2021年恢復非緊急服務。體外診斷及其他測試工具產品的需求因而谷底回升。儘管COVID-19的威脅縈繞不散,大眾的健康意識日增,意味着體外診斷試劑及耗材的需求不斷增長。
於2021年,集團的體外診斷耗材需求上升,主因在於醫院恢復服務。集團的非醫療業務主要包括於中國製造、營銷、經銷及銷售富士膠片的專業及快速沖印店彩色相紙以及工業影像產品(無損檢測X射線膠片及印製電路板膠片)。集團亦以自有品牌"Yes!Star"製造、營銷及銷售無損檢測X射線膠片。此分部的需求相對平穩,故於過往年度一直為集團帶來穩定的現金流。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.